Vivalto Partners announces the 100% acquisition of Linnea -a leading international pharmaceutical manufacturer of botanical ingredients-, formerly a joint-venture between Ipsen and Schwabe, through a primary buyout supported by management

March 31st 2025

 
 

 

Vivalto Partners announces the 100% acquisition of Linnea -a leading international pharmaceutical manufacturer of botanical ingredients


Share
Print

Education, Community and Thought Leadership


Linnea goes beyond manufacturing to support our customers, connect with the community, and educate worldwide about the potential therapeutic benefits of our ingredients

Get the latest
Linnea® news